Qian Guo

Dr. Qian Guo


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
XBXufei Bian
Xufei Bian
QGQian Guo
Qian Guo
LYLee-Fong Yau
Lee-Fong Yau
LYLing Yang
Ling Yang
XWXiaoyou Wang
Xiaoyou Wang
LCLi Chong
Li Chong
Lipid nanoparticles have shown success in targeting major organs such as the liver, spleen, and lungs, but crossing the blood-brain barrier (BBB) remains a major challenge. Effective brain-targeted delivery systems are essential for advancing gene therapy for neurological diseases but remain limited by low transport efficiency and poor nucleic acid stability. Here, we report a library of ionizable lipids based on the tetrahydroisoquinoline structure of protoberberine alkaloids, designed to improve BBB penetration via dopamine D3 receptor-mediated endocytosis. These nanoparticles offer three key advantages: enhanced brain uptake, improved nucleic acid stability through poly(A) self-assembly, and minimal immunogenicity with inherent neuroprotective properties. In murine models, they demonstrate therapeutic potential in Alzheimer’s disease, glioma, and cryptococcal meningitis. This berberine-inspired delivery system integrates precise receptor targeting with nucleic acid stabilization, offering a promising platform for brain-targeted therapeutics.

1 January 2025 in Stem Cells International
Verified
Journal Article
Open access
PWPuyu Wang
Puyu Wang
SXShengshan Xu
Shengshan Xu
QGQian Guo
Qian Guo
YZYulin Zhao
Yulin Zhao
Head and neck squamous cell carcinoma (HNSC) is an aggressive malignancy whose progression is closely associated with dysregulation of programed cell death (PCD) pathways and cancer stem cell (CSC) characteristics. To systematically screen for key pathogenic genes, this study performed single‐cell analysis on the GSE150321 dataset. The identified cell‐specific genes were intersected with PCD‐ and CSC‐related genes, yielding 24 candidate genes for preliminary screening. Further refinement using multiple machine learning (ML) algorithms identified PAK2 as the most central gene among these candidates. Analysis of TCGA and external datasets confirmed that PAK2 is significantly overexpressed in HNSC tissues, demonstrating good diagnostic value and strong association with poor patient prognosis. Functional studies revealed that PAK2 overexpression positively correlates with malignant phenotypes such as metabolic reprograming and tumor metastasis. Notably, PAK2 expression showed a significant negative correlation with antitumor immune status and negatively regulated the infiltration of multiple immune cell types. Spatial transcriptomics and single‐cell sequencing analyses revealed PAK2’s specific expression patterns within the tumor microenvironment, confirming its influence on the activity of immune‐related molecules and immunomodulators. Finally, through Connectivity Map (cMAP) screening and molecular docking, we identified the small molecule compound butein as an effective agent capable of reversing PAK2‐mediated procancer molecular features. Butein exhibits stable binding to the PAK2 protein, suggesting its potential as a targeted therapeutic agent. In summary, through multi‐omics integration analysis, this study first reveals that PAK2 plays a central role in the pathogenesis of HNSC by regulating PCD, tumor stem cell properties, and the immune microenvironment, and provides a candidate drug for its targeted therapy.

6 December 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YHYuanbin Huang
Yuanbin Huang
MXMeiqi Xu
Meiqi Xu
XMXinmiao Ma
Xinmiao Ma
WWWei Wang
Wei Wang
CSChen Shen
Chen Shen
XLXiancheng Li
Xiancheng Li
Introduction: Enfortumab vedotin (EV) and Erdafitinib are effective therapeutic drugs for bladder cancer patients following post-chemotherapy and immunotherapy. This study assessed adverse drug reactions (ADRs) from both drugs, comparing their safety profiles to guide clinical use.Methods: A retrospective descriptive analysis was conducted on ADR reports for EV and Erdafitinib from the World Health Organization (WHO)-VigiAccess database. Data on patient demographics, system organ classes (SOCs), global patient regions, symptoms, and ADRs frequencies were analyzed and compared.Results: As of 2024, 3,438 ADR reports were identified (2,257 for EV and 1,181 for Erdafitinib). The number of adverse reaction reports for EV is significantly higher than that for Erdafitinib. Among them, the SOC with the most adverse signals is gastrointestinal disorders, with the top five reports being nausea, gastrointestinal disorders, dry mouth, abdominal pain, and diarrhea. The top five reported adverse events (AEs) for EV are as follows: skin and subcutaneous tissue disorders (20.70%), general disorders and administration site conditions (14.23%), nervous system disorders (11.12%), gastrointestinal disorders (7.78%), and metabolism and nutrition disorders (6.47%). In contrast, the top five AEs for Erdafitinib are: general disorders and administration site conditions (25.36%), skin and subcutaneous tissue disorders (10.94%), gastrointestinal disorders (10.19%), eye disorders (9.21%), and injury poisoning and procedural complications (7.31%).Conclusion: Our study identified and compared potential and novel ADRs between EV and Erdafitinib, providing key insights into their safety profiles and highlighting the need for personalized treatment strategies based on individual patient risk factors.

24 October 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
HKHuadong Ke
Huadong Ke
ZZZicheng Zhang
Zicheng Zhang
ZYZhao Yu
Zhao Yu
BZBaiquan Zhang
Baiquan Zhang
RCRui Chen
Rui Chen
XLXiaohui Lou
Xiaohui Lou
Introduction: Antitumor medications such as Avastin, Berubicin, and Temozolomide have fundamentally transformed the treatment landscape for gliomas by exhibiting potent pharmacological effects on both high-grade and low-grade gliomas. This study aims to determine which anti-glioma medication presents the lowest risk for personalized use in clinical patients by assessing the adverse drug reactions (ADRs) associated with these medications as reported in the World Health Organization (WHO) VigiAcess database, and by comparing the characteristics of adverse responses among the three drugs.Methods: This investigation employs a retrospective descriptive analysis method. We compiled ADR reports for three commercially available anti-glioma medications from WHO-VigiAccess, gathering data on the disease systems and symptoms associated with ADRs, as well as the age, gender, and geographic characteristics of the patients represented in the reports. To provide a reference for clinical treatment, we analyzed the similarities and differences in the adverse reactions of the three medications by calculating the proportion of adverse reactions recorded for each drug.Results: A total of 132,471 adverse events (AEs) associated with three anti-glioma drugs were reported in VigiAccess. The analysis revealed that the ten most frequently reported AEs included bone marrow suppression, myalgia, leukopenia, thrombocytopenia, nausea, vomiting, death, rhabdomyolysis, disease progression, and a decrease in neutrophil count. The five most common categories of AEs related to anti-glioma drugs were blood and lymphatic system diseases (20,233 cases, 15.2%), general disorders and administration site conditions (26,973 cases, 20.3%), gastrointestinal dysfunction (22,061 cases, 16.7%), necessitating further investigations (18,285 cases, 13.8%), and musculoskeletal and connective tissue diseases (30,695 cases, 23.1%). Notably, the adverse events associated with Avastin were more pronounced in the category of musculoskeletal and connective tissue diseases compared to the other two drugs. Furthermore, Berubicin exhibited a particularly high proportion of blood and lymphatic system disease AEs, reaching 45.6%, which was significantly greater than those observed for the other two drugs.Conclusion: There is limited correlation between antineoplastic medications and ADRs. Current comparative observational studies indicate that these inhibitors are associated with both common and specific adverse effects documented in the ADR reports submitted to the World Health Organization (WHO).

2 October 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
QZQiang Zhou
Qiang Zhou
QXQuanlei Xie
Quanlei Xie
QLQiang Liu
Qiang Liu
HWHaojie Wang
Haojie Wang
ZZZhan Zhang
Zhan Zhang
JLJie Lin
Jie Lin
Introduction: DNA methylation inhibitors (azacitidine, decitabine) have revolutionized the treatment dilemma of myelodysplastic syndromes (MDS), a group of malignant hematopoietic disorders. This study evaluates the adverse drug reactions (ADRs) following the use of DNA methylation inhibitors in the World Health Organization (WHO) VigiAccess database and compares the characteristics of ADRs between the two drugs to select the drug with the minimum individualized risk for patients.Methods: This study employed a retrospective descriptive analysis method. We compiled ADR reports for two marketed DNA methylation inhibitors for the treatment of MDS from WHO-VigiAccess. Data collected included demographic data such as age groups, gender, and regions of global patients covered by ADR reports, as well as data on the disease systems and symptoms caused by ADRs recorded in the annual reports and reports received by WHO. By calculating the proportion of ADRs reported for each drug, we compared the similarities and differences in ADRs between the two drugs.Results: Overall, 23,763 adverse events (AEs) related to the two DNA methylation inhibitors were reported in VigiAccess. The results showed that the top 10 most common AEs were febrile neutropenia, bone marrow suppression, neutropenia, anemia, pancytopenia, leukopenia, thrombocytopenia, bone marrow failure, agranulocytosis, and hematotoxicity. The top five common types of DNA methylation inhibitor AEs were blood and lymphatic system disorders (11,178 cases, 47.0%), cardiac organ diseases (1,488 cases, 6.3%), various congenital familial genetic diseases (49 cases, 0.2%), ear and labyrinth diseases (100, 4.2%), and endocrine system diseases (57, 2.4%).Conclusion: There is no Strong correlation between DNA methylation inhibitors and ADRs. Current comparative observational studies of these inhibitors show that there are common and specific adverse reactions in the ADR reports received by WHO for these drugs. Clinicians should improve the rational use of these drugs based on the characteristics of ADRs.

29 November 2024 in Medicine
Verified
Journal Article
Open access
QGQian Guo
Qian Guo
DDDong Dong
Dong Dong
XQXinjie Qiao
Xinjie Qiao
SHShuman Huang
Shuman Huang
YZYulin Zhao
Yulin Zhao
Significant progress has been made in the pathogenesis of chronic rhinosinusitis (CRS). However, the relationship between chronic rhinosinusitis with nasal polyps (CRSwNP) and ferroptosis, as well as its underlying molecular mechanism, remains unclear. This study aimed to investigate the correlation between CRSwNP and ferroptosis and identify key gene associated with ferroptosis that could impact the diagnosis and treatment of CRS. To achieve this, gene expression profiles containing CRSwNP and CRSsNP samples were obtained from the GEO database. In addition, from the FerrDb V2 database, we acquired 2 sets of genes that are connected with ferroptosis, giving us a combined number of 260 genes associated with this particular biological process. Differential analysis and weighted gene co-expression network analysis (WGCNA) were performed on nasal tissue samples from GSE36830, leading to the identification of 1 key gene related to ferroptosis and CRS. Using stepwise regression and logistic regression analysis, we constructed a diagnostic model for CRS using ALOX15. The AUC value demonstrates that the model exhibits a strong diagnostic performance. Furthermore, the connection between immune cell infiltration in the samples and hub gene was explored, suggesting the potential significance of the hub gene in the immune response to CRS. Finally, Five drugs targeting a central gene were identified from the DrugBank database, and a few of them have exhibited efficacy in the treatment of CRS or associated ailments. In conclusion, this model holds potential for supporting the diagnosis of CRS patients, while the central gene identified may contribute to a better understanding of CRS development and drug treatment.